Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)

By sjmartinez • April 15, 2024

Weld ED, McGowan I, Anton P, Fuchs EJ, Ho K, Carballo-Dieguez A, Rohan LC, Giguere R, Brand R, Edick S, Bakshi RP, Parsons T, Manohar M, Seigel A, Engstrom J, Elliott J, Jacobson C, Bagia C, Wang L, Al-Khouja A, Hartman DJ, Bumpus NN, Spiegel HML, Marzinke MA, Hendrix CW. Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01). J Infect Dis. 2024 Apr 12;229(4):1131-1140. doi: 10.1093/infdis/jiad535. PMID: 38019657; PMCID: PMC11011183.

Tags: Digestive Diseases, HIV, Microbicide, Pharmacodynamics, Pharmacokinetics, phase 1, preexposure prophylaxis, Publications

Related Posts

Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy

Gupta S, Liu L, Demb J, Qin J, Earles A, Lamm M, Huang X, Shah SC, Chawla N, Le Y, Loeb TB, Dominitz JA, Robertson[...]

A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson’s disease

Yang JC, Situ J, Troutman R, Zhu R, Black M, Buri H, Gutta A, Tian F, Kang A, Aja E, Zeng A, Lai RW, Tan[...]

A MACHINE-BASED LEARNING MODEL FOR RECURRENCE PREDICTION AND TIMING AFTER ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S ESOPHAGUS

Akshintala V, Han S, Yan Y, Bisschops R, Brennan C, Cai Y, Codipilly DC, Cotton C, Early D, Edmundowicz SA, Eluri S, Gallegos J, Goyal[...]